STOCK TITAN

Chemours (CC) director Alister Cowan acquires 13,000 common shares in open market

(Moderate)
(Positive)
Form Type
4

Rhea-AI Filing Summary

Chemours Co director Alister Cowan purchased 13,000 shares of Chemours common stock on August 7, 2026 in an open-market transaction at a weighted average price of $15.62 per share, with individual trade prices ranging from $15.58 to $15.62. Following this purchase, Cowan’s directly owned holdings, including restricted stock units and dividend equivalent units, total 56,988.0387 shares.

Positive

  • None.

Negative

  • None.
Insider Cowan Alister
Role Director
Bought 13,000 shs ($203K)
Type Security Shares Price Value
Purchase Common Stock F1, F2 13,000 $15.62 $203K
Holdings After Transaction: Common Stock — 56,988.0387 shares (Direct)
Footnotes (2)
  1. F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at per share prices ranging from $15.58 to $15.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. F2. Includes directly owned shares, restricted stock units and dividend equivalent units.
Shares Purchased 13,000 shares Common stock acquired on August 7, 2026
Weighted Average Price $15.62 per share Open-market purchase price for 13,000 shares
Trade Price Range $15.58–$15.62 per share Prices of individual trades within the reported purchase
Holdings After Transaction 56,988.0387 shares Direct holdings including RSUs and dividend equivalent units
Net Buy Shares 13,000 shares Net share change across all reported transactions in this filing
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
restricted stock units financial
"Includes directly owned shares, restricted stock units and dividend equivalent units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
dividend equivalent units financial
"Includes directly owned shares, restricted stock units and dividend equivalent units."
Dividend equivalent units are bookkeeping credits that mirror cash dividends paid on actual shares, granted to holders of stock-based awards such as restricted stock units or deferred compensation. They matter to investors because they increase a company’s reported employee compensation cost and can lead to issuance of more shares or cash payouts over time, similar to extra pay linked to ownership that affects shareholder dilution and corporate cash flow.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Chemours (CC) director Alister Cowan report in this Form 4?

Alister Cowan reported purchasing 13,000 shares of Chemours common stock on August 7, 2026. The transaction was an open-market purchase, increasing his directly owned holdings (including RSUs and dividend equivalent units) to 56,988.0387 shares after the trade.

At what price did Alister Cowan buy Chemours (CC) shares?

Cowan’s purchase had a weighted average price of $15.62 per share. According to the disclosure, the 13,000 shares were bought in multiple trades at prices ranging from $15.58 to $15.62, with full trade details available upon request.

How many Chemours (CC) shares does Alister Cowan own after this transaction?

After the reported purchase, Cowan beneficially owns 56,988.0387 shares of Chemours common stock directly. This figure includes common shares, restricted stock units, and dividend equivalent units aggregated into the total reported post-transaction holdings.

Was the Chemours (CC) insider trade by Alister Cowan under a Rule 10b5-1 plan?

The filing does not indicate that the transaction was made under a Rule 10b5-1 trading plan. The document-level Rule 10b5-1 checkbox is marked false, and no footnote states that this purchase was pursuant to a pre-arranged plan.

What type of security did Alister Cowan acquire in Chemours (CC)?

Cowan acquired common stock of Chemours. The reported 13,000-share transaction is categorized as a non-derivative acquisition, separate from his existing restricted stock units and dividend equivalent units that are included in his total reported holdings.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cowan Alister

(Last)(First)(Middle)
C/O THE CHEMOURS COMPANY
1007 MARKET STREET

(Street)
WILMINGTON DELAWARE 19801

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/07/2026P13,000A$15.62(1)56,988.0387(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. These shares were purchased in multiple transactions at per share prices ranging from $15.58 to $15.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. Includes directly owned shares, restricted stock units and dividend equivalent units.
/s/ Eric Stein, Attorney-in-Fact08/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)